Roth Capital Has Pessimistic View of CVE:HIV FY2025 Earnings

HIVE Blockchain Technologies Ltd. (CVE:HIV) – Stock analysts at Roth Capital dropped their FY2025 earnings per share estimates for HIVE Blockchain Technologies in a research note issued on Monday, April 7th. Roth Capital analyst D. Aftahi now anticipates that the company will post earnings per share of ($0.51) for the year, down from their previous estimate of ($0.46). Roth Capital currently has a “Strong-Buy” rating on the stock. Roth Capital also issued estimates for HIVE Blockchain Technologies’ Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at $0.18 EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at $0.58 EPS.

HIV has been the subject of several other research reports. Rosenblatt Securities upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Friday, March 7th. Keefe, Bruyette & Woods upgraded shares of HIVE Blockchain Technologies to a “moderate buy” rating in a research note on Wednesday, January 8th. Five analysts have rated the stock with a strong buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

HIVE Blockchain Technologies Stock Performance

HIVE Blockchain Technologies Ltd. is a business services company in the Business Services industry.